Cardio renal metabolic complication-based pharmacotherapy Atheerotic cardiovascular disease (ASCVD) and heart failure (HF)roscl Cardiovascular disease remains the leading cause of death in people with obesity, even in the absence of diabetes
Recent data from LLY on Retatrutide (as well as other promising solutions presented at the American Diabetes Association conference) have made me consider something that seems inevitable on the surface, but the timeline of which may be greatly accelerated: obesity may have a cure (specifically - diabesity, the word for diabetes and obesity as comorbidities) in these new medications
Diabetes Therapy 15(7):16391646 Yabe D, et al (2020) Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial
Travel considerations Traveling with GLP-1 oral liquid requires planning
The standard tirzepatide titration schedule in units Tirzepatide follows a specific dose escalation pattern
Certain metabolism boosters and fat burners have been shown to reduce visceral fat when taken consistently and certain supplements like berberine and psyllium husk can help curb cravings and keep your journey on track